Detalles de la búsqueda
1.
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Mod Rheumatol
; 33(1): 73-80, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267027
2.
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Mod Rheumatol
; 32(4): 708-717, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918131
3.
Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
Br J Clin Pharmacol
; 87(4): 2014-2022, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33068028
4.
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Mod Rheumatol
; 31(3): 543-555, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33050760
5.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Ann Rheum Dis
; 78(10): 1305-1319, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350269
6.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Ann Rheum Dis
; 78(10): 1320-1332, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350270
7.
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Pharmacol Res Perspect
; 9(3): e00744, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33929089
8.
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Arthritis Res Ther
; 23(1): 221, 2021 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34429152
9.
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Rheumatol Ther
; 8(1): 425-442, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33656739
10.
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Expert Opin Pharmacother
; 21(9): 1015-1025, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32345068
11.
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis Res Ther
; 22(1): 47, 2020 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164762
12.
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis Res Ther
; 22(1): 155, 2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32576246
13.
A Novel Layered Silicate with a Helical Morphology.
Angew Chem Int Ed Engl
; 38(10): 1420-1422, 1999 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-29711586
14.
Self-sustained circadian rhythm in cultured human mononuclear cells isolated from peripheral blood.
Neurosci Res
; 66(2): 223-7, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19883700
Resultados
1 -
14
de 14
1
Próxima >
>>